Structure-Guided Design of a KMT9 Inhibitor Prodrug with Cellular Activity

Lysine methyltransferase 9 (KMT9), an obligate heterodimer (KMT9α/KMT9β), belongs to the few described Rossmann-fold histone lysine methyltransferases and monomethylates histone H4 at lysine 12 (H4K12me1). KMT9 depletion or inhibition impairs the proliferation of tumors, including prostate, lung, colon, and bladder cancer cells, underscoring its therapeutic potential. Here, we show the development of branched cofactor analogues with a methionine side chain as highly potent KMT9 inhibitors. Through structure-guided design, a basic nitrogen and 4-chlorophenoxy-2-fluorobenzene in the substrate branch contribute most to the high potency and selectivity. Due to the zwitterionic methionine side chain, the inhibitors did not show cellular activity. Importantly, an ethyl ester prodrug <b>8</b> exhibits cellular target engagement and effectively blocks the proliferation of colon cancer cell lines, further validating pharmacological inhibition of KMT9 as a promising strategy for cancer therapy.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-06-17
DOI
https://doi.org/10.1021/acs.jmedchem.4c02953
Primary Topic
Cancer-related gene regulation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Structure-Guided Design of a KMT9 Inhibitor Prodrug with Cellular Activity

Eric Metzger, Stefan Günther, Daad Sarraf, Manfred Jung et al.
Journal of Medicinal Chemistry
Cancer-related gene regulation
article

Structure-Guided Design of a KMT9 Inhibitor Prodrug with Cellular Activity

Eric Metzger, Stefan Günther, Daad Sarraf, Manfred Jung, Nicolas Barthès, Maximilian Staudt, Pankaj Mishra, Pierre Regenass, Ling Peng, Robin Warstat, Manuela Sum, Christopher Berlin, Viktor Hazai, Oliver Einsle, Bernhard Breit, Roland Schüle, Sheng Wang, Johannes Bacher, Lin Zhang, Sebastian O. Klein, Sylvia Urban, Johannes Walz, Jan Ruprecht, Nicolas Heller, Paul Kümmel
article en

Abstract

Lysine methyltransferase 9 (KMT9), an obligate heterodimer (KMT9α/KMT9β), belongs to the few described Rossmann-fold histone lysine methyltransferases and monomethylates histone H4 at lysine 12 (H4K12me1). KMT9 depletion or inhibition impairs the proliferation of tumors, including prostate, lung, colon, and bladder cancer cells, underscoring its therapeutic potential. Here, we show the development of branched cofactor analogues with a methionine side chain as highly potent KMT9 inhibitors. Through structure-guided design, a basic nitrogen and 4-chlorophenoxy-2-fluorobenzene in the substrate branch contribute most to the high potency and selectivity. Due to the zwitterionic methionine side chain, the inhibitors did not show cellular activity. Importantly, an ethyl ester prodrug <b>8</b> exhibits cellular target engagement and effectively blocks the proliferation of colon cancer cell lines, further validating pharmacological inhibition of KMT9 as a promising strategy for cancer therapy.

Journal of Medicinal ChemistryVol. 68(13)
University of Freiburg (DE), German Cancer Research Center (DE), University Medical Center Freiburg (DE), Klinik und Poliklinik für Urologie (DE), Deutsches Konsortium für Translationale Krebsforschung (DE)
Deutsche Forschungsgemeinschaft
Openalex Percentile: Top 87%
Cancer-related gene regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.